Spagnoli Giulio C, Ebrahimi Marzieh, Iezzi Giandomenica, Mengus Chantal, Zajac Paul
Department of Biomedicine, University of Basel, Institute of Surgical Research and Hospital Management (ICFS), Basel, Switzerland.
Curr Opin Drug Discov Devel. 2010 Mar;13(2):184-92.
The possibility of using the immune system of patients to control tumor outgrowth in a therapeutic setting has always been highly appealing to both clinicians and researchers. However, although cancer cells express tumor-associated antigens that can be targeted by T-cells, clinical trials suggest that the induction of specific immune responses per se may be insufficient to achieve clinical goals. Based on these trial data, in addition to experimental data revealing the complexity of mechanisms controlling immune responsiveness, a reassessment of immunotherapy procedures is underway. As a result, a second generation of antitumor treatments that includes reagents of potential pharmaceutical relevance is being developed. In this review, the most recent literature addressing issues related to immunotherapy for solid tumors is discussed.
在治疗环境中利用患者的免疫系统来控制肿瘤生长的可能性，一直以来都对临床医生和研究人员极具吸引力。然而，尽管癌细胞表达可被T细胞靶向的肿瘤相关抗原，但临床试验表明，仅诱导特异性免疫反应本身可能不足以实现临床目标。基于这些试验数据，再加上揭示免疫反应控制机制复杂性的实验数据，目前正在对免疫治疗程序进行重新评估。因此，正在开发包括具有潜在药物相关性试剂的第二代抗肿瘤治疗方法。在这篇综述中，将讨论涉及实体瘤免疫治疗相关问题的最新文献。
